ACHL
Income statement / Annual
Last year (2023), Achilles Therapeutics plc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Achilles Therapeutics plc's net income was -$69.67 M.
See Achilles Therapeutics plc’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$4.73 M |
$3.69 M |
$3.29 M |
$778,005.00 |
$303,250.00 |
$0.00 |
| Gross Profit |
-$4.73 M |
-$3.69 M |
-$3.29 M |
-$778,005.00 |
-$303,250.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$67.65 M
|
$57.26 M
|
$42.22 M
|
$22.63 M
|
$9.07 M
|
$4.80 M
|
| General & Administrative
Expenses |
$17.01 M
|
$21.12 M
|
$21.97 M
|
$11.10 M
|
$4.70 M
|
$2.10 M
|
| Selling & Marketing
Expenses |
$12.33 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$17.01 M
|
$21.12 M
|
$21.97 M
|
$11.10 M
|
$4.70 M
|
$2.10 M
|
| Other Expenses |
-$9.40 M |
$7.32 M |
$3.13 M |
$531,000.00 |
-$215,000.00 |
$0.00 |
| Operating Expenses |
$75.26 M |
$78.38 M |
$64.20 M |
$33.73 M |
$13.78 M |
$6.89 M |
| Cost And Expenses |
$75.26 M |
$78.38 M |
$64.20 M |
$33.73 M |
$13.78 M |
$6.89 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$7.32 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$4.71 M
|
$3.69 M
|
$3.29 M
|
$778,005.00
|
$303,250.00
|
$173,000.00
|
| EBITDA |
-$70.44 M
|
-$74.69 M
|
-$60.91 M
|
-$32.96 M
|
-$13.47 M
|
-$6.73 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$6.08 M
|
$7.32 M
|
$3.13 M
|
$531,000.00
|
-$215,000.00
|
$14,000.00
|
| Income Before Tax |
-$69.17 M |
-$71.07 M |
-$61.06 M |
-$33.20 M |
-$13.99 M |
-$6.89 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$491,000.00 |
$111,000.00 |
$37,000.00 |
$3,000.00 |
$130,140.00 |
$0.00 |
| Net Income |
-$69.67 M |
-$71.18 M |
-$61.10 M |
-$33.20 M |
-$13.99 M |
-$6.89 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.74 |
-1.82 |
-2.13 |
-0.82 |
-8.52 |
-12.71 |
| EPS Diluted |
-1.74 |
-1.82 |
-2.13 |
-0.82 |
-8.52 |
-12.69 |
| Weighted Average Shares
Out |
$39.97 M
|
$39.14 M
|
$28.65 M
|
$40.62 M
|
$1.64 M
|
$542,000.00
|
| Weighted Average Shares
Out Diluted |
$39.97 M
|
$39.14 M
|
$28.65 M
|
$40.62 M
|
$1.64 M
|
$542,585.00
|
| Link |
|
|
|
|
|
|
